Fig. 3

RTK/KRAS and VEGF-A/VEGFR-2 inhibition block GA progression in Tcon mice. A Representative H&E photos of Tcon3077 organoids following transduction with VEGF-A shRNA (sh.VEGF-A) and/or KRAS shRNA (sh.KRAS) or control scramble shRNA. Graph showing number of organoids greater than 100m. B Immunofluorescence (IF) photos showing CD44 (green) and cell nuclei (DAPI). Graph showing the percent of DAPI positive cells with expression of the cancer stem cell maker, CD44 in transduced Tcon3077 organoids. C Survival curve of Tcon mice treated with an oral MEK inhibitor, DC101, both MEK inhibitor and DC101, or control (n = 5–7 per group). D Representative photos of H&E slides for stomach mouse tumors. E–F IHC and graphs for CD44 and CD31 expression in mouse stomach tumors. Bars represent standard deviation. *p < 0.05 compared to control. **p < 0.05 compared to all other groups